Drugmakers Cipla and Boehringer Ingelheim (India) have entered into a partnership to co-market three new oral anti-diabetic drugs in India. They are Oboravo (empagliflozin), Oboravo Met (empagliflozin + metformin) and Tiptengio (empagliflozin + linagliptin).
Empagliflozin is approved for glucose control in patients with type-2 diabetes; it is also approved for reducing the risk of cardiovascular death in patients with type-2 diabetes and established cardiovascular disease. The empagliflozin + metformin combination Oboravo Met can be given to newly diagnosed patients of type-2 diabetes who have higher baseline HbA1c levels, a company communication said.
The empagliflozin + linagliptin combination Tiptengio is touted as the world’s first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor. In addition to a strong effect on lowering blood sugar levels, it also addresses multiple patho-physiological defects in type-2 diabetes, and is a big step towards improved management of type-2 diabetes, the note said, adding that it would reduce the pill burden for patients, thereby improving adherence to prescribed treatment.
India is second to China in the number of people who have diabetes. The size of the diabetes medicines market in India is pegged at ₹14,545 crore, with the market for oral anti-diabetic drugs being ₹10,735 crore.
Thank you for being a loyal user of Portfolio.
Portfolio will be a paid section hereon.
Please Subscribe to get access to one of our early bird packs.
Or click on Free Trial to get 14 days free trial.
What You'll Get
-
Web + Mobile
Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.
-
Exclusive Portfolio and Investment Advice, Banking, Lifestyle and Specials
Get diverse set of perspectives from our trusted experts on Portfolio, Banking, Economy, Environment and others.
-
Ad free experience
Experience cleaner site with zero ads and faster load times.
-
Personalised dashboard
Customize your preference and get a personalized recommendation of stories based on your interest.
Published on
June 29, 2020
A letter from the Editor
Dear Readers,
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill.
In these difficult times, we, at BusinessLine, are trying our best to ensure the newspaper reaches your hands every day. You can also access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all our readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. You can help us by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section.
Our subscriptions start as low as Rs 199/- per month. A yearly package costs just Rs. 999 – a mere Rs 2.75 per day, less than a third the price of a cup of roadside chai..
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism